Physicians' Academy for Cardiovascular Education

Lipids

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD - Online CME

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Online self-assessment to test eligibility for nonprescription statin therapy

Literature - Jan. 4, 2022 - Nissen SE et al. - J Am Coll Cardiol. 2021

A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD
Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.

Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.

Cost-effectiveness of a population genomic screening strategy for FH

Literature - Dec. 14, 2021 - Marquina C et al. - Eur Heart J. 2021

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

E-learning Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Many questions remain on the subject of triglycerides, EPA-based therapies and CV outcomes. Three discussants attempt to unravel the mysteries in this field.

E-learning Lp(a): from CV risk marker to therapeutic target

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this e-learning program, three experts explain why it is important to measure Lp(a) levels. Furthermore, they describe the effects of currently available lipid-lowering treatments on Lp(a) levels and talk about potential therapies for Lp(a) lowering which are currently under investigation.

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME
Prof. Stroes describes the effects of currently available lipid-lowering treatments on Lp(a) levels. Futhermore, he talks about potential RNA-based therapies for Lp(a)-lowering, which are currently under investigation.

Prof. Stroes describes the effects of currently available lipid-lowering treatments on Lp(a) levels. Futhermore, he talks about potential RNA-based therapies for Lp(a)-lowering, which are currently under investigation.

Coronary artery calcium-guided statin treatment protocol reduces predicted CV risk

Literature - Oct. 18, 2021 - Venkataraman P et al. - Atherosclerosis. 2021

A coronary artery calcium-guided statin treatment protocol in asymptomatic participants with a family history of premature CAD led to a reduction in a predicted 10-year CV risk score, compared to usual care.

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME
Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.

Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.

ESC debate | Do patients benefit from omega-3 fatty acids?

News - Sep. 7, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD - Online CME
Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Use of lipid lowering therapy in patients at high and very high CV risk in Europe

News - Aug. 31, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.